According to a recent LinkedIn post from Cooler Heads, the company is highlighting a patient interview focused on the use of its Amma scalp cooling device during cancer treatment. The post indicates that the video content emphasizes the patient’s personal experience, her rationale for choosing scalp cooling, and perceived benefits in managing treatment-related hair loss.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also reiterates that Amma is described as an innovative, FDA-cleared scalp cooling device intended to help minimize hair loss in adult cancer patients undergoing treatment for solid tumors. For investors, this emphasis on patient experience and regulatory clearance suggests Cooler Heads is positioning Amma as a differentiated supportive-care technology, which could support adoption, strengthen brand credibility in oncology settings, and potentially expand the company’s addressable market over time.